Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Summit Therapeutics Inc (SMMT) vs S&P Global Inc (SPGI) Price & Performance

Summit Therapeutics IncTrade
S&P Global IncTrade

Price performance (Past 24H)

Key statistics

Summit Therapeutics Inc vs S&P Global Inc — how do they compare? Summit Therapeutics Inc trades at $15.19 (market cap $12.06B), while S&P Global Inc trades at $409.63 (market cap $120.48B). The key difference: S&P Global Inc is far larger — about 10× Summit Therapeutics Inc's market cap, and S&P Global Inc pays a 0.95% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

SMMTSPGI
Market Cap
$12.06B$120.48B
Sector
HealthFinancials
52-Week High
$26.98$534.79
52-Week Low
$12.55$370.42
Enterprise Value
$11.39B$131.97B
Dividend Yield
0.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.

Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.

S&P Global Inc

S&P Global (SPGI) trades at $409.55, down 0.34% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $4.83, beating estimates, with revenue growth accelerating to $15.34B in 2025. Analyst consensus remains strongly bullish with 85.7% buy ratings and a $523.20 price target, representing 28% upside potential from current levels.

SPGI presents a compelling investment case with robust profitability (30.5% net margin) and strategic AI partnerships, though technical indicators suggest near-term pressure. The key risk involves maintaining premium valuations (P/E 24.9) amid economic uncertainty, while institutional confidence remains high with aggressive buyback programs supporting shareholder returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT

About S&P Global Inc

S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.

Read more on SPGI